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The role of the prosthetic axilloaxillary loop access
as a tertiary arteriovenous access procedure
Thomas W. Kendall Jr, MD, David L. Cull, MD, Christopher G. Carsten III, MD,
Corey A. Kalbaugh, MS, Anna L. Cass, MPH, and Spence M. Taylor, MD, Greenville, SC
Purpose: In the last decade, the Dialysis Outcome Quality Initiative (DOQI) Guidelines have enhanced the longevity of
patients with end-stage renal disease (ESRD) on hemodialysis. Consequently, surgeons are increasingly challenged to
provide vascular access for patients in whom options for access in the upper extremity have been expended. This situation
is even more problematic in the morbidly obese patient on hemodialysis. Our group previously reported a high rate of
infection and need for secondary interventions in obese patients with prosthetic femorofemoral accesses. We now report
a series of patients who underwent placement of a prosthetic axilloaxillary loop access. This study presents our technique
and evaluates our results, particularly as they relate to the obese patient.
Methods: From January 1998 to May 2006, 34 prosthetic axilloaxillary loop accesses were placed in 32 patients with
ESRD. Eleven patients (12 accesses) were obese, as defined by a body mass index >30 kg/m2. Median follow-up was 16
months. Kaplan-Meier analysis was used to determine primary and secondary patency as well as patient survival for the
entire cohort and for the obese and nonobese patient cohorts. Survival curves were compared using the log-rank test for
equality over strata.
Results: The secondary patency rate was 59% at 1 year (median, 18 months). The 1-year patient survival was 69%.
Infection occurred in 15% patients. Comparison of the obese vs nonobese cohorts demonstrated no statistically significant
difference in 1-year primary patency (36% vs 10%, P  .17) or secondary patency (71% vs 65%, P  .34). There were no
infections in the obese cohort.
Conclusion: These data show that the prosthetic axilloaxillary loop access has acceptable outcomes and should be
considered the tertiary vascular access procedure of choice in the obese patient on hemodialysis. ( J Vasc Surg 2008;48:
389-93.)Implementation of the National Kidney Foundation/
Dialysis Outcome Quality Initiative (DOQI) has resulted
in improvements in the medical management of patients on
hemodialysis and a decrease in their mortality rate.1 One
consequence of this increase in survival is that patients may
outlive the arteriovenous (AV) access sites in their upper
extremities and must face the placement of an access else-
where. The most common site for AV access placement
outside the upper extremity is in the femoral position.
However, prosthetic femoral accesses are associated with a
significant risk of infection, access-related leg ischemia, and
graft failure.2,3 For the obese patient, the risk and technical
challenge of prosthetic femoral access placement is even
greater. A large study published by our institution on
prosthetic femoral accesses showed that obese patients
required a significantly higher number of interventions to
maintain access patency compared with nonobese pa-
tients.4
Since 1998 our group has performed prosthetic axil-
loaxillary loop access placement for patients in whom access
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pended. As a result of our early experience, we have come
to prefer the prosthetic axilloaxillary loop access rather than
prosthetic femorofemoral access in the morbidly obese
patient. The purpose of this study is to review our tech-
nique, patient selection, and results with the prosthetic
axilloaxillary loop access and to determine its role as an AV
access in the obese patient population.
MATERIAL AND METHODS
Approval for this study was obtained from the Green-
ville Hospital System University Medical Center Institu-
tional Review Board. The vascular surgery registry was
retrospectively reviewed to identify all cases of prosthetic
axilloaxillary loop access procedures performed between
January 1998 andMay 2006. Data were also obtained from
office, dialysis clinic, and hospital records. Collected data
included patient demographics, anthropometrics, medical
comorbidities, and complications. Obesity was defined us-
ing the Centers for Disease Control and Prevention classi-
fication of a body mass index (BMI) of 30 kg/m2.
Kaplan-Meier analysis was used to determine primary
patency, secondary patency, and patient survival for the
entire cohort as well as for the obese and nonobese patient
groups. Primary patency was defined as the time from
access placement until first access thrombosis or any inter-
vention designed to maintain patency. Secondary patency
was defined as the interval from the time of access place-
ment until access abandonment. Survival curves were com-
pared using the log-rank test for equality over strata.
389
JOURNAL OF VASCULAR SURGERY
August 2008390 Kendall et alPatient selection and operative technique. Patients
were selected for prosthetic axilloaxillary loop access place-
ment only if vascular access options in the upper extremity
were exhausted. If a significant difference in blood pressure
between the extremities existed, the axillary artery on the
side with the highest pressure was the preferred donor
vessel, and an arteriogramwas considered. Venograms were
obtained to confirm patency and exclude stenosis of the
central veins. In addition to anatomic considerations, the
handedness of the patient also influenced the choice of a
right-sided or left-sided access placement.
All procedures were performed with general anesthesia.
The patient was placed in the supine position with the arm
extended 90° on an arm board. An incision was made one
fingerbreadth below the clavicle from the sternoclavicular
joint to the coracoid process. The pectoralis major muscle
fibers were split. The clavipectoral fascia was divided, and
the axillary vein was exposed and mobilized. Beneath the
axillary vein, the axillary artery was exposed just distal to its
exit from the thoracic outlet. Branches of the axillary artery,
such as the supreme thoracic artery, were ligated and di-
vided as necessary to achieve adequate mobilization of the
axillary artery.
A 6-mm polytetrafluoroethylene (PTFE) graft (W. L.
Gore & Associates, Flagstaff, Ariz) was tunneled in a loop
configuration on the chest wall. A transverse counterinci-
sion was made cephalad to the areola to assist in tunneling.
Before the graft was tunneled, the patient was placed in the
reverse Trendelenburg position to situate the breast in its
dependent location. This maneuver was performed to ac-
Fig 1. Left chest wall loop arteriovenous graft. A, Arterial limb;
V, venous limb.
Table 1. Arteriovenous access placement during the
study period
Arteriovenous access
Upper
extremity
Lower
extremity
Chest
wall Overall
Prosthetic, No. (%) 1369 (86) 181 (12) 34 (2) 1584
Autogenous 1721 . . . . . . 1721curately determine graft length and is particularly impor-tant for patients with pendulous breasts. The graft was
tunneled using a transverse counterincisionmade just ceph-
alad to the areola. The venous limb of the graft was posi-
tioned laterally on the chest. The venous end of the graft
was oriented nearly parallel to the axillary vein and was
directed centrally. The arterial end of the graft was posi-
tioned perpendicular to the axillary artery. The graft was
sewn end-to-side to the axillary artery and vein (Fig 1).
Contraindications to placement of an axilloaxillary AV
graft included central venous stenosis or occlusion. Breast
size is not a contraindication to the procedure. The grafts
are allowed to mature the standard 2 to 3 weeks before use.
RESULTS
Between January 1998 and May 2006, our group cre-
ated 1721 autogenous AV accesses and 1584 prosthetic AV
accesses (Table I). This study cohort comprised 32 patients
who received 34 prosthetic axilloaxillary loop accesses. All
patients considered for axilloaxillary loop accesses demon-
strated patent central veins on preoperative venography,
and none of the patients had central venous stents. Twelve
of the accesses were placed in 11 obese patients, and 22
accesses were placed in 21 nonobese patients. Patient de-
mographics for each cohort are reported in Table II. The
obese and nonoboese cohorts were not statistically signifi-
cant different in the sex, race, prevalence of diabetes melli-
tus, or mean age.Median patient follow-up was 16months.
Two patients died early for an overall 30-day mortality
rate of 6.3%. These patients were not hospitalized when
they died, and the ultimate cause of death was undeter-
mined. Thrombosis 30 days of graft placement occurred
in three of 34 grafts placed (8.8%). Nonthrombotic com-
plications occurred in 26% and included bleeding, infec-
Table II. Patient demographics of 32 patients
undergoing axilloaxillary loop access
Variable
Obese
(n  11)
Nonobese
(n  21)
Overall
(n  32) P
Age, mean  SD y 50.9  14.2 59.9  11.6 56.8  12.2 .09
Male sex, No. (%) 3 (27.3) 10 (47.6) 13 (40.7) .45
Race, No. (%)
White 7 (63.6) 6 (28.6) 13 (40.7) .07
Black 4 (36.4) 15 (71.4) 19 (59.3)
Diabetic, No. (%) 6 (54.5) 13 (61.9) 19 (54) .72
Table III. Number and type of complications of
axilloaxillary loop access
Complication, No (%)
Obese
(n  12)
Nonobese
(n  22)
Overall
(n  34) P
Thrombosis (30 days) 1 (8.3) 2 (9.1) 3 (8.8) .99
Bleeding 1 (8.3) 2 (9.1) 3 (8.8) .99
Infection 0 (0.0) 5 (22.7) 5 (14.7) .14
Venous hypertension 0 (0.0) 1 (4.5) 1 (2.9) .99
Access-related ischemia 0 (0.0) 0 (0.0) 0 (0) . . .tion, and venous hypertension (Table III). No access-
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 2 Kendall et al 391related hand ischemia occurred. No patient in this series
presented with symptoms of superior vena cava syndrome
or significant upper extremity venous hypertension after the
ultimate failure of the axilloaxillary access. One patient
required reoperation for bleeding. Two hematomas devel-
oped after access attempts at dialysis units. Upper extremity
venous hypertension developed in one patient, manifested
by upper extremity swelling after axilloaxillary access place-
ment, which required graft ligation.
The overall primary patency rate was 17% at 1 year. The
median time to the first AV access intervention was 5
months. The overall secondary patency rate was 59% at 1
year and 37% at 2 years. The secondary patency at 1 and 2
years was, respectively, 71% and 53% for obese patients and
54% and 29% for nonobese patients. The difference in
secondary patency rates between the obese and nonobese
patients was not significant (P  .14; Fig 2). The median
AV access survival was 18 months (range, 10-36 months).
The overall patient survival rate was 69% at 1 year and
61% at 3 years (median survival, 38 months). No statisti-
cally significant difference was found in patient survival
between the obese and nonobese patient groups (P  .34;
Fig 3) or in complications or patency.
DISCUSSION
Obtaining vascular access for the patient on hemodial-
ysis, once the options in the upper extremities have been
exhausted, can be technically challenging and associated
with a high incidence of complications, particularly in the
morbidly obese patient. The most common AV access
procedure performed outside the upper extremities is in the
femoral position. In most patients exposure of the femoral
vessels for graft placement is relatively straightforward. The
procedure can be performed under local or regional anes-
thesia, and compared with other AV access options, com-
plications are more easily managed. However, alternative
procedures must be used for patients with significant aor-
Fig 2. Secondary patency for obese cohort (dashed line) and
nonobese cohort (solid line).toiliac occlusive disease, bilateral iliofemoral vein thrombo-sis, or in whom femoral AV access sites have been ex-
pended.
Although prosthetic axilloaxillary access was first de-
scribed in 1978, the literature reporting the outcome with
this technique is scant and primarily limited to small case
series.5-7 In 1996 McCann8 reported outcomes for 26
patients who underwent prosthetic axilloaxillary access
placement. The secondary patency for AV accesses in his
series was 60% at 18months, which is nearly identical to the
patency rate achieved in our series.
The technique for prosthetic axilloaxillary access place-
ment described by previous authors is a straight graft con-
figuration from the axillary artery to the contralateral axil-
lary vein.6-8 McCann’s series also included a small number
of patients with grafts that were looped from the axillary
artery to the ipsilateral internal jugular vein. Both of these
configurations orient the graft away from the central veins,
which makes future percutaneous intervention for access
thrombosis more difficult.
The configuration we use is a loop from the axillary
artery to the ipsilateral axillary vein. The venous limb is
oriented lateral to the arterial limb. This configuration
allows the venous limb of the graft to be directed toward
rather than away from the central veins, which facilitates
percutaneous intervention should a stenosis develop at the
venous anastomosis. Another advantage of using the ipsi-
lateral axillary artery and vein is that it preserves the con-
tralateral axillary vessels as a site for future AV access
placement. One patient in our series underwent bilateral
prosthetic axilloaxillary looped access placement.
No case of access-related hand ischemia or congestive
heart failure occurred in either McCann’s series or in ours.8
In McCann’s series, a number of prosthetic axilloaxillary
accesses were placed in patients in whom previous AV
accesses in the ipsilateral extremity had caused access-
related hand ischemia. In our series, prosthetic axilloaxillary
accesses were placed in two patients who had experienced
hand ischemia related to a previous AV access in the ipsi-
Fig 3. Patient survival in the obese cohort (dashed line) and in the
nonobese cohort (solid line).lateral extremity. Hand ischemia did not recur in either of
oveno
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that a history of upper extremity access-related ischemia
does not preclude AV access placement based off the ipsi-
lateral axillary artery.
The secondary patency rates reported for accesses based
off the femoral vessels range from 43% to 54% at 2 years.4,9
These results are similar to the 2-year secondary patency of
37% for prosthetic axilloaxillary access in the current series.8
Because the procedures to place the access and to manage
complications, such as infection, are usually technically
easier for the femoral-based accesses, the prosthetic femo-
rofemoral access has become the preferred AV access pro-
cedure when upper extremity sites are exhausted.4
However, the prosthetic femorofemoral access has sig-
nificant disadvantages for patients who are obese. A previ-
ous report of prosthetic femorofemoral accesses from our
Fig 4. Algorithm for arteriinstitution found significantly higher rates of access reinter-vention in obese compared with nonobese patients.4 Sub-
sequently, we reported the outcome of a separate series of
46 AV accesses that were based off the superficial femoral
artery in the midthigh.9 This modification of the standard
prosthetic femorofemoral access helps avoid the node-bearing
tissue of the groin and the overlying abdominal pannus.
For the obese patient, however, the abdominal pannus
that overlies the groin and the depth of the femoral vessels
in the midthigh make femoral access placement more tech-
nically difficult and may increase the risk of complications.
We have found that obese patients generally have less
subcutaneous fat over the axillary vessels than the femoral
vessels, and the vascular exposure and tunneling for pros-
thetic axilloaxillary access placement is easier than the femoral-
based access. Because of experience with femorofemoral
and axilloaxillary AV access, we favor the prosthetic axil-
us (AV) access placement.loaxillary loop access for the morbidly obese patient (Fig 4).
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differences between groups, but the results do suggest that
the infection and secondary patency rates for prosthetic
axilloaxillary accesses between obese and nonobese patients
are similar. Furthermore, the overall infection rate of 15%
for prosthetic axilloaxillary access in this series compares
favorably with the reported 21% to 41% infection rates
reported for prosthetic femorofemoral accesses.2-4,9
Although the Kaplan-Meier curves and tabulated com-
plication data appear to suggest a difference in graft patency
and infection rates between the obese and nonobese co-
horts, no statistically significant difference was found be-
tween the two groups in our series. We do not believe that
obese patients have lower infection rates than nonobese
patients. However, despite the small numbers of patients in
the obese group, we do believe that our study shows that
the infection rate in obese patients is equivalent to the
nonobese patient group and compares quite favorably with
AV grafts in the thigh position.
The difficulty in establishing andmaintaining AV access
for the morbidly obese patient, once options in the upper
extremity have been expended, might prompt some to
consider placing a cuffed dialysis catheter and to forego
placing a prosthetic AV access altogether. However, the
high complication rate associated with catheter-based he-
modialysis is well established,10 and patient survival for the
obese patient on dialysis rivals that of the nonobese patient.
In this study and in our previous report of patients who
underwent prosthetic femorofemoral access, the median
patient survival for obese patients was 38 and 41 months,
respectively.4 We believe that despite the challenges posed
by AV access placement in the obese patient, in most cases,
their life expectancy on dialysis justifies attempts at an
axilloaxillary AV access placement in preference to catheter-
based dialysis.
CONCLUSIONS
The results of this study suggest that the prosthetic
axilloaxillary loop access should be considered before the
femorofemoral access in the morbidly obese patient when
upper extremity sites are exhausted. The procedure has
acceptable patency rates and may be associated with a lower
infection rate compared with prosthetic femorofemoral
accesses. For the nonobese patient in whom vascular access
options are unavailable in both the upper extremity and
femoral position, the prosthetic axilloaxillary loop accessshould be considered before resorting to dialysis with a
cuffed dialysis catheter. The loop configuration of the
ipsilateral axilloaxillary access, which enables the venous
end of the graft to be oriented toward the central veins,
facilitates the percutaneous treatment of venous stenosis
and may enhance the secondary patency of these accesses.
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